Pasithea Therapeutics Corp.
Moat Score — Pasithea Therapeutics Corp.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | PAS-004's claimed chemistry-based differentiation - avoiding a primary alcohol/hydroxamate metabolic liability found in earlier MEK inhibitors - is real IP, but it remains clinically unproven and sits in a field with at least six already-approved competing drugs. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage biotech, Pasithea has no cost advantage; it is purely an R&D-spending organization funded by capital markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved product, Pasithea has no current pricing power; any future pricing power is entirely speculative pending trial results. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in clinical-stage MEK inhibitor development. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product, there are no prescriber or patient switching costs for PAS-004 yet. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The MEK inhibitor market already supports at least six approved competing drugs from major pharma companies plus multiple NF1-PN-focused developers, showing this is a crowded field rather than one where scale creates exclusivity. |